Cytophage Technologies (TSXV:CYTO) LT-Debt-to-Total-Asset : 0.16 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cytophage Technologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.16.

Cytophage Technologies's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Mar. 2024 (0.16). It may suggest that Cytophage Technologies is progressively becoming more dependent on debt to grow their business.

Cytophage Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Cytophage Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies LT-Debt-to-Total-Asset Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.02

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			-	-	-	-	0.16

Cytophage Technologies LT-Debt-to-Total-Asset Calculation

Cytophage Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	5.461
	=

Cytophage Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1.389	/	8.745
	=

Cytophage Technologies (TSXV:CYTO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cytophage Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.